Thymosin alpha 1 and HIV-1: recent advances and future perspectives.
Matteucci. Claudia C; Grelli. Sandro S; Balestrieri. Emanuela E; Minutolo. Antonella A; Argaw-Denboba. Ayele A; Macchi. Beatrice B; Sinibaldi-Vallebona. Paola P; Perno. Carlo Federico CF; Mastino. Antonio A; Garaci. Enrico E
Key Findings
- TA1 can improve immune system homeostasis in HIV‑infected patients on ART
- It may reduce persistent inflammation and improve cytotoxic T‑cell function
- The peptide shows benefits across many conditions, but specific dosing for HIV isn’t settled
Practical Outcomes
- TA1 could be explored as an add‑on to standard HIV therapy to help the immune system recover, but there’s no clear dosing guideline yet. Enthusiasts should wait for more clinical trials and discuss any use with a healthcare professional before trying it.
Summary
Thymosin‑alpha‑1 is a small protein that can help balance the immune system, and studies suggest it may boost immune recovery in people with HIV who are on antiretroviral drugs, but the evidence is still mostly from lab and early clinical work.
Abstract
In spite of the consistent benefits for HIV-1 infected patients undergoing antiretroviral therapy, a complete immune reconstitution is usually not achieved. Actually, antiretroviral therapy may be frequently accompanied by immunological unresponsiveness, persistent inflammatory conditions and inefficient cytotoxic T-cell response. Thymosin alpha 1 is a thymic peptide that demonstrates a peculiar ability to restore immune system homeostasis in different physiological and pathological conditions (i.e., infections, cancer, immunodeficiency, vaccination and aging) acting as multitasking protein depending on the host state of inflammation or immune dysfunction. This review reports the present knowledge on the in vitro and in vivo studies concerning the use of thymosin alpha 1 in HIV-1 infection. Recent findings and future perspectives of therapeutic intervention are discussed.
Study Information
pubmed
2017
2017-01-20T00:00:00.000Z
10.2217/fmb-2016-0125
47
95